TxCell extends phase I/II trial for Crohn’s disease
TxCell, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, will extend treatment of patients included in the Crohn’s disease phase I/II study (CATS1) with Ovasave, a type 1 regulatory T cell based immunotherapy.
CATS1 (Crohn And Tr1 Study) is a phase I/II trial designed to evaluate the tolerability and explore the efficacy of Ovasave in patients with severe chronic active Crohn’s disease, who failed current treatments, including biologics. In the first part of the study completed in April 2010, Ovasave administration was well tolerated and showed evidence of a beneficial effect in the overall population of patients. The now approved extension of CATS1 is destined to address the requests from investigators of continuing treatment in patients that benefited from the initial Ovasave administration.